Provided is an influenza mucosal vaccine compositionpreparationapplication thereof. This composition contains an antigen fusion protein which includes an influenza virus antigena Type IIb heat-labile enterotoxin A subunit. Immunization with the antigen fusion protein induces cellularhumoral immune responses, including systemicmucosal immune responses, against a specific in

The technology optimizes the antigen protein expression system, so that the structural protein Erns of CFSV converts insoluble proteins into soluble proteins during the production process. The breakthrough of this technology allows the antigen protein to be applied to the development of an immune attachment screening platform, as a specialized differential diagnostic reagents can distinguish between virus-infectedvaccinated pigs, which can be applied to the monitoring system of virus transmission rangevaccination